Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits
International Journal of Applied Biology and Pharmaceutical Technology · 2026 · 17 (1)
DOI: 10.26502/ijabpt.202144 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Applied Biology and Pharmaceutical Technology, 2026. Verfasst von Abdulkadir Abdu und 8 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Abdu, A., Bakrey, H., Abdelrahim, I., Awad, Z., Fikak, Y. A., Atem, T. D., Justine, A. K., Abdelaziz, M. A. A., & Eltaib, L. (2026). Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits. International Journal of Applied Biology and Pharmaceutical Technology, 17(1). https://doi.org/10.26502/ijabpt.202144
Vancouver
Abdu A, Bakrey H, Abdelrahim I, Awad Z, Fikak YA, Atem TD, et al. Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits. International Journal of Applied Biology and Pharmaceutical Technology. 2026;17(1). doi:10.26502/ijabpt.202144
BibTeX
@article{Abdu2026,
author = {Abdu, Abdulkadir and Bakrey, Hossamaldeen and Abdelrahim, Israa and Awad, Zeinab and Fikak, Yassir Abubakar and Atem, Tambe Daniel and Justine, Angima Kibari and Abdelaziz, Mazin Aboobaida Abdalla and Eltaib, Lina},
title = {Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits},
journal = {International Journal of Applied Biology and Pharmaceutical Technology},
year = {2026},
volume = {17},
number = {1},
doi = {10.26502/ijabpt.202144}
}
EUVIMED